Search Results
Sep 08, 2026, 08:15 ET 禮邦醫藥 AP308 治療 IgA 腎病的新藥臨床試驗申請獲美國 FDA 批准
由臨床前研究邁入臨床開發階段。關於 AP308AP308 是一款旨在實現 IgA 腎病功能性治癒的同類首創工程化重組 IgA 蛋白酶。該藥物基於源自人體共生菌 Thomasclavelia ramosa 的 IgA 蛋白酶開發，可切割 IgA1、半乳糖缺陷型 IgA1（Gd-IgA1）、多聚 IgA 及 IgA 免疫複合物，並可直接清除於腎小球的 IgA 免疫複合物及補體 C3 沉積；在臨床前研究中可於數分鐘內起效，且不影響 IgG、IgM 等其他免疫球蛋白。[1] 2022
More news about: 禮邦醫藥
Sep 08, 2026, 08:05 ET Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy
recombinant IgA protease aiming for the functional cure of IgAN. The drug is developed based on an IgA protease derived from Thomasclavelia ramosa, a human commensal bacterium, and can cleave IgA1, galactose-deficient IgA1 (Gd-IgA1), polymeric IgA and IgA immune complexes, and directly clears IgA immune
More news about: Alebund Pharmaceuticals
Sep 08, 2026, 07:04 ET LA CIUDAD DE CHICAGO SE ASOCIA CON CHICAGO RIVER SWIM PARA RELANZAR «THE BIG JUMP» Y AMPLIAR EL NÚMERO DE PARTICIPANTES A 750 NADADORES
reconexión de las personas con los ríos y los cursos de agua urbanos.El deportista olímpico mexicano Jorge Andrés Iga César representará a México en «The Big Jump» este viernes. Iga César compitió en los Juegos de París 2024 y ostenta el récord nacional de México en los 200 metros libres. Ha ganado
More news about: A Long Swim
Sep 08, 2026, 07:04 ET CITY OF CHICAGO PARTNERS WITH CHICAGO RIVER SWIM TO RE-LAUNCH "THE BIG JUMP," EXPAND FIELD TO 750 SWIMMERS
that inspiration as part of his vision for bringing a river swim to Chicago.Mexican Olympic swimmer Jorge Andrés Iga César will represent Mexico in The Big Jump on Friday. Iga César competed at the 2024 Paris Games and holds Mexico's national record in the 200-meter freestyle. He has earned four
More news about: A Long Swim
Sep 08, 2026, 07:04 ET DIE STADT CHICAGO ARBEITET MIT „CHICAGO RIVER SWIM" ZUSAMMEN, UM „THE BIG JUMP" NEU ZU STARTEN UND DIE TEILNEHMERZAHL AUF 750 SCHWIMMER ZU ERWEITERN
seiner Vision an, das Schwimmen im Fluss nach Chicago zu bringen.Der mexikanische Olympia-Schwimmer Jorge Andrés Iga César wird Mexiko am Freitag bei „The Big Jump" vertreten. Iga César nahm an den Olympischen Spielen 2024 in Paris teil und hält den mexikanischen Landesrekord über 200 Meter Freistil.
More news about: A Long Swim
Sep 08, 2026, 07:04 ET CITY OF CHICAGO PARTNERS WITH CHICAGO RIVER SWIM TO RE-LAUNCH "THE BIG JUMP," EXPAND FIELD TO 750 SWIMMERS
that inspiration as part of his vision for bringing a river swim to Chicago.Mexican Olympic swimmer Jorge Andrés Iga César will represent Mexico in The Big Jump on Friday. Iga César competed at the 2024 Paris Games and holds Mexico's national record in the 200-meter freestyle. He has earned four
More news about: A Long Swim
Sep 08, 2026, 07:04 ET LA VILLE DE CHICAGO S'ASSOCIE À CHICAGO RIVER SWIM POUR RELANCER « THE BIG JUMP » ET PORTER LE NOMBRE DE PARTICIPANTS À 750 NAGEURS
inspiration à sa volonté de faire venir la nage en rivière à Chicago.Le nageur olympique mexicain Jorge Andrés Iga César représentera le Mexique vendredi lors de l'événement « The Big Jump ». Iga César a participé aux Jeux de Paris 2024 et détient le record national mexicain du 200 mètres nage libre. Il
More news about: A Long Swim
Sep 04, 2026, 13:04 ET Pathlock Recognized as a Representative Vendor in the 2026 Gartner® Market Guide for Identity Governance and Administration
According to Gartner, this research "highlights emerging risks and opportunities, enabling informed decisions in the evolving IGA market."DENVER, Sept. 4, 2026 /PRNewswire/ --
More news about: Pathlock
Sep 02, 2026, 07:00 ET Gartner named SafePaaS in the 2026 Market Guide for Identity Governance and Administration (IGA) for cybersecurity leaders facing growing threats from AI agents
federated identity architecture that connects across all sources of identities and entitlements. Organizations can easily upgrade to SafePaaS from legacy IGA to improve identity visibility, access governance, regulatory compliance, risk management, and transaction monitoring. SafePaaS customers achieve rapid
More news about: SafePaaS
Aug 26, 2026, 06:47 ET Alebund Pharmaceuticals Announces 2026 Interim Results
upstream IgA production by modulating B-cell pathways (such as APRIL/BAFF), AP308 acts by directly cleaving and clearing pathogenic IgA and IgA immune complexes that have already formed, including IgA deposited in the glomeruli.Preclinical data. In the humanized mouse model of IgA nephropathy,
More news about: Alebund Pharmaceuticals
Aug 26, 2026, 06:44 ET 禮邦醫藥發佈 2026 年中期業績
AP308：一款旨在實現 IgA 腎病功能性治愈的同類首創工程化重組 IgA 蛋白酶AP308 為一款工程化重組 IgA 蛋白酶藥物，源自人體共生菌 Thomasclavelia ramosa，可特異性切割人 IgA1 鉸鏈區上游位點。有別於現有通過調節 B 細胞通路（如 APRIL/BAFF）以減少上游 IgA 生成的療法，其作用機制為直接切割並清除已生成的致病性 IgA 及 IgA 免疫復合物，包括已沉積於腎小球的 IgA。臨床前數據：在人源化 IgA 腎病小鼠模型中，單次給藥即可使循環人 IgA1 較對照組降低約 90%，且在整個治療周期（8
More news about: 禮邦醫藥
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
(anti-IL-17A monoclonal antibody) in Chinese mainland, Hong Kong SAR, Macau SAR, and Taiwan region. The complement inhibitor FXS6837 for the treatment of IgA nephropathy and other glomerular diseases associated with complement dysregulation initiated Phase 2b clinical trials in Chinese mainland. The DPP1 inhibitor
More news about: Fosun Pharma
Aug 21, 2026, 03:24 ET 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
demonstrating Best-In-Class potential. SSS68 (long-acting anti-APRIL/BAFF bispecific antibody) has obtained IND approvals in both China and the U.S. for IgA nephropathy, making it the only long-acting bispecific antibody for this indication to enter clinical trials in China.Dermatology and Weight
More news about: 3SBio Inc.
Aug 20, 2026, 10:09 ET Keymed Biosciences Announces 2026 H1 Results and Business Updates
a randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the safety and efficacy of CM313 (SC) injection in subjects with IgA nephropathy. As of the date of this announcement, this study is in the patient enrollment phase.CM518D1: Continued to advance
More news about: Keymed Biosciences
Aug 19, 2026, 09:14 ET XtalPi Holdings Announces 2026 Interim Results
The platform has built six siRNA programs spanning IgA nephropathy, metabolic diseases and central nervous system disorders; more than half have completed in vivo efficacy evaluations, and the most advanced program has reached the PCC stage. The lead IgA nephropathy program generated non-human primate efficacy
More news about: XtalPi Holdings Limited
Aug 19, 2026, 09:00 ET Axiad Research Finds Enterprises Are More Confident Than Ready for Post-Quantum Cryptography
into one trustworthy picture, ranks each risk by what it would cost the business, names the owner, and routes the fix into systems like ServiceNow, IGA, and PAM. Built for large, regulated, multi-IdP enterprises by a team that has run identity where failure was never an option. Trusted by Fortune 500
More news about: Axiad IDS, Inc.
Aug 18, 2026, 08:00 ET Kedrion Biopharma Announces the Extension of a U.S. Agreement with Grifols to Support Long-Term and Continued Access to GAMMAKED®
contains trace amounts of IgA (average 46 micrograms/mL). Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions. It is contraindicated in IgA deficient patients with antibodies against IgA and history of hypersensitivity
More news about: Kedrion Biopharma
Aug 12, 2026, 06:30 ET Boulevard Bio Launches with $65 Million from Deerfield and World-Class Founders to Advance Precision Immunology Pipeline
healthy volunteer data for lead candidate BLVD101, a dual BAFF/APRIL-targeting bispecific antibody, supporting a 12-week (quarterly) dosing interval in IgA nephropathy (IgAN). Founded by pioneers in B cell biology and incubated by Deerfield Management within Deerfield Discovery and Development (3DC), the
More news about: Boulevard Bio
Aug 10, 2026, 16:02 ET Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
supporting the TRAP degrader platform in IgA nephropathy: In May 2026, the Company reported updated Phase 1b data from our ongoing study of BHV-1400 in patients with IgAN. BHV-1400 administered subcutaneously achieved mean reductions of pathogenic Gd-IgA1 of greater than 60% within 48 hours and approximately
More news about: Biohaven Ltd.
Aug 07, 2026, 07:02 ET 禮邦醫藥AP301新藥上市申請獲國家藥監局受理
來更優的治療方案。目前，公司已擁有7款在研候選產品及1款商業化產品（美信羅®），其中AP301、AP306 及AP303 三款在研產品已進入臨床階段，分別處於臨床 III 期、II 期及 I 期，其中AP301 的中國關鍵III 期臨床試驗已完成，全球多區域臨床試驗（MRCT）正在進行。整體產品組合覆蓋慢性腎臟病及其並發症的多個適應症，包括高磷血症、腎性貧血、IgA 腎病、糖尿病腎病、局灶節段性腎小球硬化及常染色體顯性多囊腎病。公司已在江蘇揚州建成生產基地，以支持AP301等管線產品未來的商業化生產，並已取得江蘇省藥品監督管理局頒發的《藥品生產許可證》（B 類）；同時，公司已組建腎科專科銷售團隊，負責相關產品在中國的商業化推廣。更多信息，請訪問：
More news about: 禮邦醫藥
Aug 07, 2026, 06:34 ET Alebund's AP301 NDA Accepted for Review by China's NMPA
(Phase II) and AP303 (Phase I). Together they address chronic kidney disease (CKD) and its complications, including hyperphosphatemia, renal anemia, IgA nephropathy, diabetic kidney disease, FSGS and ADPKD. Alebund has built a manufacturing site in Yangzhou, Jiangsu to support the future commercial manufacturing
More news about: Alebund Pharmaceuticals
Aug 03, 2026, 09:00 ET Trazeetravel.com Announces Winners of Annual Awards
TAP Air PortugaliGA İstanbul AirportNinth Consecutive
More news about: Trazee Travel
Aug 03, 2026, 09:00 ET WhereverFamily Announces Winners of Ninth Annual Awards
YearBest Family-Friendly Domestic AirportTampa International AirportBest Family-Friendly International AirportiGA İstanbul AirportFifth Consecutive Year Best Family-Friendly Airport DiningChicago O'Hare
More news about: WhereverFamily
Jul 26, 2026, 21:27 ET 晶泰科技Kodexia™：首個生成式AI+第一性原理的siRNA研發平台獲新進展，管線進入PCC確認階段
於「生成式 AI+第一性原理」 的乾濕閉環 siRNA 藥物開發平台 Kodexia™ 迎來關鍵里程碑，並在 CPIC 2026 首屆大國新藥全球會議上公佈了多款自研管線的最新進展。作為公司 「AI+機器人」 智能藥物研發平台向核酸藥物模態的延伸，Kodexia™ 平台在一款面向 IgA 腎病的 siRNA 管線中僅用 7 個月，便獲得非人靈長類（NHP）藥效數據，活性與長效性均優於同靶點的臨床階段參照分子，有望於近期——即項目立項後 9 個月內確定PCC分子（臨床前候選化合物），研發週期較行業平均的 12 到 18 個月顯著縮短。該臨床前平行對照試驗數據初步驗證了平台 AI 模型在活性與長效性預測上的準確度，也表明
More news about: 晶泰科技
Jul 21, 2026, 07:00 ET Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
escape arm.The primary endpoint of the ZENITH AD studies is IGA 0/1 response at Week 24 with EASI-75 response at Week 24 as a key secondary endpoint. For registration in jurisdictions outside the U.S., the co-primary endpoints are IGA 0/1 response and EASI-75 response at Week 24. Other key secondary
More news about: Nektar Therapeutics